Index RUT
P/E -
EPS (ttm) -1.06
Insider Own 40.66%
Shs Outstand 49.13M
Perf Week 6.72%
Market Cap 343.62M
Forward P/E -
EPS next Y -0.77
Insider Trans -0.40%
Shs Float 29.85M
Perf Month 12.89%
Income -52.32M
PEG -
EPS next Q -0.21
Inst Own 32.20%
Short Float 3.56%
Perf Quarter 5.89%
Sales 79.39M
P/S 4.33
EPS this Y 15.04%
Inst Trans -3.34%
Short Ratio 5.03
Perf Half Y 45.01%
Book/sh 2.03
P/B 3.37
EPS next Y 20.82%
ROA -31.24%
Short Interest 1.06M
Perf Year 97.97%
Cash/sh 2.35
P/C 2.91
EPS next 5Y -
ROE -44.01%
52W Range 1.04 - 8.45
Perf YTD 32.36%
Dividend Est. -
P/FCF -
EPS past 5Y -30.17%
ROI -38.43%
52W High -19.17%
Beta 2.71
Dividend TTM -
Quick Ratio 10.50
Sales past 5Y 72.98%
Gross Margin 85.80%
52W Low 556.73%
ATR (14) 0.39
Dividend Ex-Date -
Current Ratio 11.01
EPS Y/Y TTM 27.81%
Oper. Margin -65.36%
RSI (14) 55.64
Volatility 4.27% 5.84%
Employees 214
Debt/Eq 0.34
Sales Y/Y TTM -2.60%
Profit Margin -65.90%
Recom 2.43
Target Price 7.38
Option/Short Yes / Yes
LT Debt/Eq 0.34
EPS Q/Q 18.72%
Payout -
Rel Volume 0.40
Prev Close 6.78
Sales Surprise 0.13%
EPS Surprise 15.65%
Sales Q/Q -8.95%
Earnings Aug 01 AMC
Avg Volume 211.21K
Price 6.83
SMA20 4.10%
SMA50 0.45%
SMA200 23.89%
Trades
Volume 84,158
Change 0.74%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-21-24 Initiated
Lake Street
Buy
$10
Sep-12-23 Downgrade
William Blair
Outperform → Mkt Perform
Sep-12-23 Downgrade
Piper Sandler
Overweight → Neutral
$15 → $5.50
Sep-12-23 Downgrade
BofA Securities
Neutral → Underperform
$10 → $4.50
Aug-24-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$12 → $8.40
Jul-10-23 Downgrade
Citigroup
Buy → Neutral
$15 → $9
Jan-06-23 Upgrade
Stifel
Hold → Buy
$10 → $15
Oct-04-22 Initiated
Needham
Hold
Jul-26-22 Initiated
Stifel
Hold
$10
Feb-03-22 Initiated
William Blair
Outperform
Jan-07-22 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$36 → $27
Show Previous Ratings
Aug-21-24 09:36AM
Aug-20-24 04:05PM
Aug-02-24 11:30AM
(Thomson Reuters StreetEvents) -14.96%
Aug-01-24 06:45PM
04:05PM
04:05PM
Loading…
Jul-18-24 04:05PM
Jun-10-24 04:05PM
May-28-24 04:05PM
(GlobeNewswire) +7.54%
+5.51%
08:30AM
May-07-24 04:05PM
May-06-24 10:02AM
May-03-24 01:37PM
01:04PM
(Thomson Reuters StreetEvents)
May-02-24 09:55PM
06:20PM
04:05PM
Loading…
04:05PM
Apr-30-24 11:02AM
Apr-29-24 03:55PM
01:59PM
11:21AM
10:51AM
08:05AM
Apr-18-24 04:05PM
Apr-10-24 04:05PM
Apr-02-24 04:05PM
Mar-26-24 04:05PM
Mar-08-24 02:53PM
09:16AM
(Thomson Reuters StreetEvents)
Mar-07-24 10:35PM
09:53PM
05:50PM
Loading…
05:50PM
04:05PM
Feb-22-24 04:05PM
Feb-21-24 10:25AM
Feb-14-24 04:05PM
Jan-23-24 04:05PM
(GlobeNewswire) -9.68%
-11.28%
Jan-14-24 05:25PM
Jan-08-24 04:05PM
Dec-28-23 09:15AM
Dec-18-23 04:05PM
Dec-08-23 08:05AM
Nov-13-23 03:40PM
Nov-12-23 09:40AM
Nov-07-23 04:05PM
Oct-26-23 05:30PM
Oct-24-23 04:05PM
Oct-19-23 04:05PM
Oct-12-23 04:05PM
Oct-03-23 08:30AM
Sep-12-23 09:53AM
02:55AM
Sep-11-23 04:06PM
04:05PM
Aug-30-23 04:05PM
Aug-03-23 06:35PM
04:05PM
Jul-24-23 09:55AM
Jul-20-23 04:05PM
08:30AM
Jul-17-23 12:00PM
Jun-21-23 08:30AM
Jun-09-23 04:05PM
May-23-23 08:30AM
May-09-23 09:55AM
May-06-23 11:30AM
May-04-23 06:45PM
04:05PM
May-01-23 04:05PM
(GlobeNewswire) +9.41%
-5.67%
Apr-26-23 04:05PM
Apr-20-23 04:05PM
Apr-19-23 01:57PM
(Simply Wall St.) +14.47%
Apr-13-23 04:05PM
Apr-11-23 05:22AM
Apr-03-23 04:05PM
Mar-30-23 08:00AM
Mar-23-23 11:25AM
Mar-14-23 11:22AM
Mar-13-23 05:25PM
04:05PM
Mar-09-23 08:30AM
Feb-23-23 04:05PM
Feb-22-23 04:05PM
Feb-14-23 07:10AM
Jan-26-23 08:30AM
Jan-09-23 04:20PM
01:15PM
Jan-04-23 10:00AM
Dec-29-22 09:10AM
Dec-13-22 01:09PM
Dec-08-22 08:30AM
Nov-22-22 08:30AM
Nov-16-22 05:21AM
Nov-10-22 05:35PM
04:05PM
Nov-03-22 10:00AM
08:30AM
Oct-20-22 05:20PM
Oct-14-22 10:51AM
Oct-04-22 03:38PM
Sep-29-22 08:30AM
Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
HAYDEN JEREMY B. Chief Legal Officer Jul 02 '24 Sale 6.21 5,055 31,402 163,565 Jul 03 07:54 PM Badawi David Chief Technology Officer Jul 01 '24 Sale 6.42 3,128 20,072 1,759,648 Jul 03 07:54 PM Badawi Paul President and CEO Jul 01 '24 Sale 6.42 12,569 80,655 5,738,160 Jul 03 07:54 PM Park Sam Boong Chief Operating Officer Jul 02 '24 Sale 6.21 3,525 21,897 258,229 Jul 03 07:52 PM Bauerlein Alison Chief Financial Officer Jul 02 '24 Sale 6.21 10,497 65,207 402,685 Jul 03 07:50 PM Bauerlein Alison Chief Financial Officer May 17 '24 Sale 5.42 13,066 70,870 413,182 May 20 08:56 PM HAYDEN JEREMY B. Chief Legal Officer Apr 03 '24 Sale 5.08 4,893 24,852 168,620 Apr 04 07:26 PM Badawi Paul President and CEO Apr 03 '24 Sale 5.08 12,571 63,848 5,750,729 Apr 04 07:25 PM Badawi David Chief Technology Officer Apr 03 '24 Sale 5.08 3,128 15,887 1,762,776 Apr 04 07:24 PM Park Sam Boong Chief Operating Officer Apr 03 '24 Sale 5.08 3,414 17,340 261,754 Apr 04 07:24 PM Bauerlein Alison Chief Financial Officer Apr 03 '24 Sale 5.08 10,123 51,415 426,248 Apr 04 07:19 PM Badawi Paul President and CEO Jan 17 '24 Sale 5.16 15,917 82,195 5,319,539 Jan 19 04:49 PM Badawi David Chief Technology Officer Jan 17 '24 Sale 5.16 3,414 17,630 1,642,157 Jan 19 04:43 PM HAYDEN JEREMY B. Chief Legal Officer Jan 17 '24 Sale 5.16 4,538 23,434 10,318 Jan 19 04:39 PM Park Sam Boong Chief Operating Officer Jan 17 '24 Sale 5.16 5,443 28,108 100,735 Jan 19 04:28 PM D1 Capital Partners L.P. 10% Owner Dec 27 '23 Sale 5.86 2,852,036 16,712,931 3,000,000 Dec 29 08:30 PM Encrantz Staffan Director Nov 30 '23 Buy 3.46 140,777 486,638 1,012,150 Dec 01 07:39 PM Encrantz Staffan Director Nov 29 '23 Buy 3.50 3,223 11,280 871,373 Dec 01 07:39 PM Encrantz Staffan Director Nov 28 '23 Buy 3.46 253,669 877,137 868,150 Nov 28 08:32 PM Encrantz Staffan Director Nov 27 '23 Buy 3.31 246,331 815,947 614,481 Nov 28 08:32 PM Encrantz Staffan Director Nov 24 '23 Buy 3.09 21,855 67,427 368,150 Nov 28 08:32 PM Badawi David Chief Technology Officer Nov 24 '23 Option Exercise 0.11 150,000 16,500 1,631,196 Nov 28 08:16 PM Encrantz Staffan Director Nov 20 '23 Buy 2.25 79,234 178,189 236,733 Nov 22 06:19 PM Encrantz Staffan Director Nov 21 '23 Buy 2.48 68,477 169,535 305,210 Nov 22 06:19 PM Encrantz Staffan Director Nov 22 '23 Buy 2.50 41,085 102,708 346,295 Nov 22 06:19 PM Encrantz Staffan Director Nov 17 '23 Buy 2.19 126,664 277,293 157,499 Nov 20 09:45 PM Encrantz Staffan Director Nov 16 '23 Buy 2.00 339 678 30,835 Nov 20 09:45 PM Encrantz Staffan Director Nov 14 '23 Buy 2.00 3,462 6,914 30,496 Nov 16 05:44 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite